Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22708715 | 0.96 | ESR2 (0.33) | LIMK1ESR2ESR1 | |
| SCHEMBL22708596 | 0.96 | LIMK1 (0.33) | LIMK1ESR2ESR1 | |
| SCHEMBL22708603 | 0.95 | NPC1 (0.31) | — | |
| SCHEMBL22199997 | 0.94 | PTGER1 (0.32) | ESR2PTGER1ESR1MEN1CSF1R | |
| SCHEMBL22708357 | 0.93 | ESR2 (0.33) | LIMK1ESR2ESR1 | |
| SCHEMBL22708360 | 0.93 | ESR2 (0.33) | LIMK1ESR2ESR1 | |
| SCHEMBL21913814 | 0.92 | PTGER1 (0.33) | ESR2PTGER1ESR1MEN1CSF1R | |
| SCHEMBL22708749 | 0.91 | ESR2 (0.32) | LIMK1ESR2 | |
| SCHEMBL22708821 | 0.91 | LIMK1 (0.34) | LIMK1ESR2ESR1 | |
| SCHEMBL22708619 | 0.91 | LIMK1 (0.34) | LIMK1ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11588110-B2 | Heterocyclic compound and organic light emitting device comprising the same | LT MATERIALS CO., LTD. (KR) | 2023-02-21 | — | — | US | disclosed |
| US-20200373499-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | LT MATERIALS CO., LTD. (KR) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11588110-B2 | Heterocyclic compound and organic light emitting device comprising the same | CRY1, CYP1A1, CYP1B1 | LIMK1 541/4885ESR2 700/4885PTGER1 170/4885 |
| US-20200373499-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME | CRY1, CYP1A1, CYP1B1 | LIMK1 541/4885ESR2 700/4885PTGER1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.